A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.

Trial Profile

A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2013

At a glance

  • Drugs Tadalafil (Primary) ; Sildenafil
  • Indications Erectile dysfunction
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Dec 2012 New source identified and integrated (German Clinical Trials Register record: DRKS00004102).
    • 21 Oct 2010 Last checked against ClinicalTrials.gov record.
    • 18 Apr 2010 Results presented at the 25th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top